This publication was commissioned by Roche Products (New Zealand) Ltd following a Roche organised and funded educational event held on Thursday 20th November 2025 covering clinical trial evidence and real-world data for faricimab (Vabysmo®) in the treatment of neovascular age-related macular degeneration (nAMD). From 1st December 2025, faricimab is funded for nAMD and DMO for patients who meet predefined criteria. This publication was reviewed and edited by Roche to ensure accuracy and compliance with the Medicines New Zealand Code of Practice. Treatment decisions based on these data are the full responsibility of the prescribing physician; consult the Data Sheet at www.medsafe.govt.nz before prescribing.
The guest speaker for the educational event was Dr Carl Danzig from The Advanced Retina Institute in Florida, USA. New Zealand perspectives were provided by Auckland ophthalmologists Dr Leo Sheck and Dr Joel Yap.
Please login below to download this issue (PDF)